Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $37 to $38.